Genetic Analysis (GEAN) Q2 2024 earnings summary

Executive summary

• Q2 2024 operating income was NOK 5.0 million, with a net loss of NOK -4.8 million; H1 2024 net loss improved to NOK -10.6 million from NOK -12.8 million year-over-year.

• Reagent kit sales surged 135% year-over-year in Q2 2024, driving recurring revenue growth.

• New product launches and expanded lab installations in Europe and the US supported market expansion.

• Secured NOK 4.4 million innovation loan and raised NOK 5.42 million in equity for US business expansion.

• Leadership changes included a new chairperson and CFO resignation.

Financial highlights

• Q2 2024 sales revenue rose 21% to NOK 4.4 million; H1 2024 sales were NOK 7.7 million, nearly flat year-over-year.

• Operating expenses in H1 2024 decreased by NOK 4.9 million compared to H1 2023, reflecting cost-saving measures.

• Cash and cash equivalents at period end were NOK 7.0 million, down from NOK 11.9 million a year earlier.

• Equity ratio improved to 62.2% from 60.8% year-over-year.

• Earnings per share for H1 2024 were NOK -0.25, an improvement from NOK -0.51 in H1 2023.

Outlook and guidance

• Strong interest in microbiome testing and new customer growth expected to drive future sales.

• FDA approval of microbiome-based therapeutics and global corporate interest seen as positive market drivers.

• Anticipates doubling GA-map® system installations in 2024 compared to 2023.